ESR1 and breast carcinoma: Initial clinical trials demonstrated activity in women with advanced metastatic HR+ breast cancer [24], including patients whose tumors had acquired ESR1 mutations, leading to the Phase 3 randomized EMERALD clinical trial in 2nd–3rd line setting, reporting a statistically significant improvement in Progression Free Survival (PFS) [25].